Newsroom

Sera Prognostics, Inc., announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023, after the close of the market.

Sera Prognostics Inc. announced that the company will present at the upcoming Cowen Health Care Conference March 6-8, 2023 in Boston and the Oppenheimer 33rd Annual Healthcare Conference held to be held virtually March 13-15, 2023.

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay

Sera Prognostics and Fors Marsh are collaborating to provide Sera’s PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.

Sera Prognostics Inc. announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes).

SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today…

Sera Prognostics announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market.

Sera Prognostics Inc., focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera’s PreTRM® Test to members of Sonrava Health’s employer-sponsored health insurance program.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), and Banner Health today announced that Sera’s PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members.

Salt Lake City – August 10, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2022.